1. UNAIDS/WHO global AIDS statistics. AIDS Care. 11(2):253–2641999.
2. Fauci AS. The AIDS epidemic. Considerations for the 21
st century. N Engl J Med 341:1046–10501999.
3. Wortley P, Fleming P. AIDS in women in the United States. Recent trends. JAMA 278:911–9161997.
4. Centers for Disease Control and Prevention. US HIV and AIDS cases reported through December 1999. HIV/AIDS Surveillance Report 11(2):1–421999.
5. Rosenberg P, Biggar R. Trends in HIV incidence among young adults in the United States. JAMA 279:1894–18991998.
6. Sullivan P, Do A, Ellenberger D. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States. J Infect Dis 181:463–4692000.
7. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global HIV/AIDS epidemic. June. 2000;Geneva: 2000.
8. Kang MR, Cho YK, Chun J, Kim YB, Lee IS, Lee HJ, Kim SH, Kim YK, Yoon KJ, Yang JM, Kim JM, Shin YO, Kang C, Lee JS, Choi KW, Kim DG, Fitch WM, Kim SY. Phylogenetic analysis of the nef gene reveals a distinctive monophyletic clade in Korean HIV-1 cases. J Acquir Immune Defic Syndr 17:58–681998.
10. Pallela FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853–8601998.
11. Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, Shin DH, Lee JS, Choe K. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis 29:1524–15281999.
12. Kim JM, Cho GJ, Hong SK, Chung JS, Chang KH, Kim CO, Cho JH, Park YS, Kim HY, Choi YH, Song YG. Characteristics of epidemiology and clinical features of HIV infection/AIDS in Korea (in press).
13. Hong SK, Park YS, Cho JH, Roh HJ, Kim HY, Chang KH, Song YG, Kim JM. Antiviral effect and safety of triple combination therapy in human immunodeficiency virus (HlV)-infected persons. Korean J Med 58:582–5892000.
14. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus: a cohort study. Lancet 353:2093–20991999.
15. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. Arch Intern Med 160:2050–20562000.
16. Chang KH, Kim JM, Hong SK, Song YG, Lee HC, Lim SK. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? In : 8th Conference on Retroviruses and Opportunistic Infections; 2001; Abst. 648. p. 238.
17. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunod efficiency virus infection and the acquired immuno deficiency syndrome. J Clin Endocrinol Metab 74:1045–10521992.
18. Cameron DW, Heath-Chiozzi M, Danner S. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351:543–5491998.
19. Mulligan K, Grunfeld C, Tai VW. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23:35–432000.
20. Chang KH, Kim JM, Hong SK, Song YG, Lee HC, Lim SK. Does race influence bone mineral density in HIV-infected individuals receiving HAART? In : 8 th Conference on Retroviruses and Opportunistic Infections; 2001; Abst. 630. p. 233.
21. Little S, Daar E, D”Aquila R. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142–11491999.